Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs
Monday, 19 May 2025 ()
SUZHOU, China, May 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological, an innovator in novel cancer therapeutics.Β Porton Advanced will provide end-to-end CDMO services for Hualong's Multi-Activated T Cell (MATC) therapy, from process optimization to regulatory submission, accelerating its development progress.
Hualong Biological 's research team has established a strong clinical foundation for its MATC platform through multiple investigator-initiated trials (IITs), demonstrating significant therapeutic benefits across various solid tumor indications. Porton Advanced will leverage its industry-leading process development platforms, GMP manufacturing capabilities, and proven regulatory expertise to optimize the MATC therapy's CMC strategy and facilitate its transition from research to clinical development.
Mingguang Huang, Chairman of Hualong Biological, commented: "We are delighted to partner with Porton Advanced. Their comprehensive CDMO technical expertise and regulatory experience in cell therapy will significantly enhance our MATC program's development efficiency and IND preparation timeline. Together, we're committed to advancing this innovative therapy into clinical trials to benefit patients worldwide."
Andrew Chen, CFO of Porton Advanced, stated: "Collaborating with Hualong Biological marks a strategic expansion of our CDMO services in cell therapy. We are honored to provide regulatory-compliant, high-quality MATC CMC services to support their IND application. Porton Advanced is committed to supporting partners through our integrated technology platform and regulatory experience to bring cutting-edge therapies to patients faster."
*About Hualong Biological*
Founded in 2012, Henan Hualong Biological is a national high-tech enterprise in China specializing in cell technology development and applications. Aligned with its strategic vision of integrating cell storage, research, therapeutic development, and clinical applications, Hualong Biological primarily focuses on cell banking, cell therapy development, and related cell technology services.
The company has established advanced expertise in immune and stem cell technologies, with several core technical parameters ranking among industry leaders. Its comprehensive platform addresses the full spectrum of cell therapy development, from fundamental research to clinical implementation. Through continuous technological innovation and strategic market expansion, Hualong Biological has emerged as a leading cell therapy enterprise in Henan Province. The company remains committed to consolidating its influential position within the cellular technology industry.
*About Porton Advanced*
Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization.
Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV,etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sqft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 18 global IND approvals from NMPA, FDA, and Medsafe, with 5 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.
Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner.
For more information about Porton Advanced, please visit: www.portonadvanced.com.
|
||||
|
|
||||
You Might Like |
||||
